الفهرس 
C HRONIC M YELOID L EUKEMIAOnly 14 pages are availabe for public view
 |  | from | 160 |  |  |
| | | from | 160 | | |
Abstract
Background: chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by a reciprocal translocation between chromosomes 9 and 22 [t (9; 22) (q34; q11)], creating the Philadelphia chromosome and bringing together the Breakpoint Cluster Region (BCR) and Abelson (ABL1) genes.
The tyrosine kinase inhibitors (TKI), of which imatinib is the most widely used, block BCR-ABL1 tyrosine kinase activity by the competitive inhibition of ATP binding, resulting in a dramatic reduction in the differentiation and proliferation of BCR-ABL1 positive cells.
Most patients treated with imatinib achieve hematological, cytogenetic and molecular remissions and are unlikely to progress to blastic transformation. However, a minority will fail to respond, and a further subset of patients loses their initial response.
The mechanisms underlying imatinib resistance however are not fully understood but include inadequate compliance, mutations in the BCR-ABL1 tyrosine kinase domain and changes in intracellular pathways independent of BCR-ABL1 signaling. Several studies have investigated whether variations in the expression and function of organic cation transporter 1(OCT1, also termed SLC22A1), which is thought to transport imatinib into the cell, determines responsiveness to imatinib
A number of studies have described an association between high OCT1 expression (measured by real time quantitative polymerase chain reaction) and improved outcome in CML patients treated with imatinib. However, other studies showing that imatinib response in CML patients are independent of OCT1 level.
.
The relevance of Organic Cation Transporter 1 (OCT1) on the response to treatment in adult patients with chronic-phase chronic myeloid leukemia
Egyptian Journal Of Hematology & Bone Marrow Transplantation Volume 6, Issue 6 October 2018
Aim of the work: Is to assess properly the relevance of organic cation transporter1on the response of adult patients with chronic myeloid leukemia to treatment
Patients and Methods: This Study is a cross sectional study that was conducted on 41 patients with chronic myeloid leukemia (CML) in Clinical Hematology Unit in Ain-Shams University Hospitals in Cairo, Egypt and 10 controls.
Result: The OCT1 level in the patient group ranged from 0.29-85.73 ng/μl (mean 5.64), and in the control group it ranged from 0.28-15.13 ng/μl (mean 2.45).There was no statistically significant correlation between the human OCT1level and imatinib response.
Moreover, there was no statistically significant difference between patients with high and low human OCT1level regarding event free survival. Also, there was no statistically significant difference between the patient and control groups as regard the human OCT1.
Conclusion: The human OCT1 is not a valid biomarker for imatinib response and resistance in CML patients, and the cellular uptake of imatinib in CML patients is independent of the human OCT1 level